HUTCHMED (China) Limited (HCM) Discusses Antibody Targeted Therapy Conjugates Platform and Lead Candidate HMPL-A251 in R&D Update Transcript
PresentationDavid NgHead of Investor Relations & Capital Strategies Hello, everyone. Good evening and good morning. Thank you for joining HUTCHMED 2025 R&D Day event. For your reference, you can go to our website to download today's presentation slides. The performance and results of operations of the HUTCHMED Group contained within this presentation are historical in nature, and the past performance is no guarantee of future results. [Operator Instructions] So now let me welcome our CMO and Head of R&D, ...